K2M acquires rights to PSD’s injectable polymer technology
K2M said that its commitment to a new biomaterials R&D division signals its continued drive to being a market leader in the complex spine market. In furtherance of
Daiichi Sankyo and Merck & Co (MSD) have voluntarily withdrawn their biologics license application (BLA) for ifinatamab deruxtecan, aimed at treating adult patients with extensive-stage small cell lung cancer (ES-SCLC) following disease progression after platinum-based chemotherapy.